Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 15, 2011, authorized by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 1,370,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,176 pence per share; lowest price paid was 1,153 pence per share.
- Treasury Holdings (Settled): 489,664,284 shares (8.63% of total issued share capital).
- Treasury Holdings (Including Unsettled): 491,624,284 shares (9.49% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,181,403,135 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 1,370,000 shares. Consequently, the total number of shares held in Treasury increased, raising the percentage of total voting rights held in Treasury to 9.49% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intention is to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,181,403,135) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (9.49% including unsettled shares).
- Review the specific price range paid (1,153 to 1,176 pence) for the March 15, 2011 transaction.